Nicotine abstinence syndrome precipitated by an analog of neuropeptide FF

Pharmacology Biochemistry and Behavior

Volumn 54, Issue 3, 1996, Pages 581-585

  Malin, David H ^a,b   Lake, J Ronald ^a   Short, Paul E ^a   Blossman, J Brandon ^a   Lawless, Brent A ^a   Schopen, Christina K ^a   Sailer, Elizabeth E ^a   Burgess, Kevin ^c   Wilson, Owen B ^d  

^a UNIVERSITY OF HOUSTON CLEAR LAKE   (United States)

^b UH CL Box 237 ^*  (United States)

^c TEXAS A AND M UNIVERSITY   (United States)

^d BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Antiopiate peptides; Dansyl compounds; Endogenous opioid peptides; F8Famide; Neuropeptide FF; Nicotine; Nicotine abstinence; Nicotine dependence; Nicotine withdrawal

Indexed keywords

NEUROPEPTIDE FF; NICOTINE;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG DEPENDENCE; DRUG EFFECT; DRUG WITHDRAWAL; MALE; NONHUMAN; OPIATE ADDICTION; PRIORITY JOURNAL; RAT; SMOKING CESSATION; WITHDRAWAL SYNDROME;

ANIMALIA; RODENTIA;

EID: 0029972941     PISSN: 00913057     EISSN: None     Source Type: Journal    
DOI: 10.1016/0091-3057(95)02279-1     Document Type: Article

References (54)

1. Aghajanian, G. K. Tolerance of locus coeruleus neurones to morphine and suppression of withdrawal response by clonidine. Nature 276:186-188; 1978.
2. Allard, M.; Geoffe, S.; Legendre, P.; Vincent, J. D.; Simonnet, G. Characterization of rat spinal cord receptors to FLFQPQRFamide, a mammalian morphine modulating peptide, a binding study. Brain Res. 500:167-176; 1989.
3. Atherton, E.; Sheppard, R. C. Solid phase peptide synthesis, a practical approach. Oxford: IRL Press; 1989.
4. Brussaard, A. J.; Kits, K. S.; Ter Matt, A.; Mudler, A. H.; Schoffelmeer, N. M. Peripheral injection of DNS-RFa, a FMRFa agonist, suppresses morphine-induced analgesia in rats. Peptides 9:735-739; 1989.
5. Conte-Devolx, B.; Oliver, C.; Giraud, P.; Gillioz, P.; Castanas, E.; Lissitsky, J. C.; Boudouresque, F.; Millet, Y. Effect of nicotine on in vivo secretion of melanocorticotropic hormones in the rat. Life Sci. 28:1067-1073; 1981.
6. Davenport, K. E.; Houdi, A. A.; VanLoon, G. R. Nicotine protects against mu-opioid receptor antagonism by beta-funal-trexamine: Evidence for nicotine-induced release of endogenous opioid. Neurosci. Lett. 113:40-46; 1990.
7. 2-like peptide, blocks opiate effects on ileum contractions. Peptides 14:1005-1009; 1993.
8. Felix, A. M.; Wang, C.-T.; Heimer, E. P.; Fournier, A. Applications of BOP reagent in solid phase synthesis 11. Solid phase side-chain to side-chain cyclizations using BOP reagent. Int. J. Pept. Protein Res. 31:231-238; 1988.
9. Fielding, S.; Wilker, J.; Hynes, M.; Szewczak, M.; Novick, W. J.; Lal, H. A comparison of clonidine with morphine for antinociceptive and antiwithdrawal actions. J. Pharmacol. Exp. Ther. 207:899-905; 1978.
10. Flores, C. M.; Hulihan-Giblin, B. A.; Hornby, P. J.; Lumpkin, M. D.; Kellar, K. J. Partial Characterization of a neurotransmitter pathway regulating the in vivo release of prolactin. Neuroendocrinology 55:519-528; 1992.
11. Flores, C. M.; Hulihan-Giblin, B. A.; Kellar, K. J. Naltrexone blocks nicotine-induced prolactin release. Neuropharmacology 28:1287-1290; 1989.
12. Gicquel, S.; Mazarguil, H.; Allard, M.; Simonnet, G.; Zajac, J. M. Analogues of F8Famide resistant to degradation, with high affinity and in vivo effects. Eur. J. Pharmacol. 222:61-67; 1992.
13. Gilbert, D. G.; Meliska, C. J.; Williams, C. L.; Jensen, R. A. Subjective correlates of cigarette-induced elevations of β-endorphin and cortisol. Psychopharmacology (Berlin) 106:275-281; 1992.
14. Glassman, A. H.; Jackson, W. K.; Walsh, T.; Roose, S. P.; Rosenfeld, B. Cigarette craving, smoking withdrawal and clonidine. Science 226:864-866; 1984.
15. Glassman, A. H.; Stetner, F.; Walsh, B. T.; Raizman, P. S.; Fleiss, J. L.; Cooper, T. B.; Covey, L. S. Heavy smokers, smoking cessation, and clonidine: Results of a double-blind, randomized trial. JAMA 259:2863-2866; 1988.
16. Gold, M. S.; Redmond, D. E.; Kleber, H. D. Clonidine blocks acute opiate withdrawal symptoms. Lancet 2:599-602; 1978.
17. Gorelick, D. A.; Rose, J.; Jarvik, M. E. Effect of naloxone on cigarette smoking. J. Subst. Abuse 1:153-159; 1989.
18. Gossop, M.; Powell, J.; Grey, S.; Hajek, P. What do opiate addicts and cigarette smokers mean by "craving"? A pilot study. Drug Alcohol Depend. 26:85-87; 1990.
19. Hebert, K. M.; Malin, D. H.; Witherspoon, W. E.; Collins, M.; Harris, K.; Liu, T.-A.; Smith, D. A.; Avera, C.; Ho, K.-K.; Pal, B.; Burgess, K. Subcutaneous dansyl-RFamide, an analog of neuropeptide FF, precipitates morphine abstinence. Int. Behav. Neurosci. Soc. Abstr. 3:65; 1994.
20. Hexum, T. D.; Russett, L. R. Plasma enkephalin-like peptide response to chronic nicotine infusion in guinea pig. Brain Res. 406:370-372; 1987.
21. Hodson, C. A.; Davenport, A.; Price, G.; Burden, H. W. Naltrexone treatment attenuates the inhibitory effect of nicotine on serum LH in rats. Life Sci. 53:839-846; 1993.
22. Houdi, A. A.; Pierzchala, K.; Marson, L.; Palkovits, M.; Van Loon, G. R. Nicotine-induced alteration in Tyr-Gly Gly and Metenkephalin in discrete brain nuclei reflects altered enkephalin neuron activity. Peptides 12:161-166; 1991.
23. Jensen, R. A.; Gilbert, D. G.; Meliska, C. J.; Landrum, T. A. Characterization of a dose-response curve for nicotine-induced conditioned taste aversion in rats: Relationship to elevation of plasma β-endorphin concentration. Behav. Neural Biol. 53:428-440; 1990.
24. Karras, A.; Kane, J. M. Naloxone reduces cigarette smoking. Life Sci. 27:1541-1545; 1980.
25. Kavaliers, M. Inhibitory influences of mammalian FMRFamide (Phe-Met-Arg-Phe-amide)-related peptides on nociception and morphine-and stress-induced analgesia in mice. Neurosci. Lett. 115:307-312; 1990.
26. Kivipelto, L.; Rubenstein, J.; Yang, H.-Y.T.; Panula, P. Ontogeny of the F8Famide-like (morphine-modulating) peptides in the central nervous system of rats. J. Comp. Neurol. 304:2-21; 1991.
27. Koob, G. F.; Maldonado, R.; Stinus, L. Neural substrates of opiate withdrawal. Trends Neurosci. 15:186-191; 1992.
28. Lake, J. R.; Hammond, M. V.; Shaddox, R. C.; Hunsicker, L. M.; Yang, H.-Y. T.; Malin, D. H. IgG from neuropeptide FF antiserum reverses morphine tolerance in the rat. Neurosci. Lett. 132:29-32; 1991.
29. Lake, J. R.; Hebert, K. M.; Payza, K.; Deshotel, K. D.; Hausam, D. D.; Witherspoon, W. E.; Arcangeli, K. R.; Malin, D. H. Analog of neuropeptide FF attenuates morphine tolerance. Neurosci. Lett. 146:203-206; 1992.
30. Magnuson, D. S. K.; Sullivan, A. F.; Simonnet, G.; Request, B. P.; Dickenson, A. H. Differential interactions of cholecystokinin and FLFQPQRF-NH2 with mu and delta opioid antinociception in the rat spinal cord. Neuropeptides 16:213-218; 1990.
31. Malin, D. H.; Lake, J. R.; Smith, D. A.; Jones, J. A.; Morel, J.; Claunch, A. E.; Stevens, P. A.; Payza, K.; Ho, K.-K.; Liu, J.; Ham, I.; Burgess, D. H. Subcutaneous injection of an analog of neuropeptide FF prevents naloxone-precipitated morphine abstinence syndrome. Drug Alcohol Depend. 40:37-42; 1995.
32. Malin, D. H.; Lake, J. R.; Arcangeli, K. R.; Deshotel, K. D.; Hausam, D. D.; Witherspoon, W. E.; Carter, V. A.; Yang, H.-Y. T.; Pal, B.; Burgess, K. Subcutaneous injection of an analog of neuropeptide FF precipitates morphine abstinence syndrome. Life Sci. 53:PL261-266; 1993.
33. Malin, D. H.; Lake, J. R.; Carter, V. A.; Cunningham, J. S.; Wilson, O. B. Naloxone precipitates nicotine abstinence syndrome in the rat. Psychopharmacology (Berlin) 112:339-342; 1993.
34. Malin, D. H.; Lake, J. R.; Carter, V. A.; Cunningham, J. S.; Wilson, O. B. The nicotine antagonist mecamylamine precipitates nicotine abstinence syndrome in the rat. Psychopharmacology (Berlin) 115:180-184; 1994.
35. 2-like mammalian peptide precipitates opiate withdrawal syndrome in the rat. Peptides 11:277-280; 1990.
36. 2-like mammalian octapeptide: Possible role in opiate dependence and abstinence. Peptides 11:969-972; 1990.
37. Malin, D. H.; Lake, J. R.; Leyva, J. E.; Hammond, M. V.; Rogillio, R. B.; Arcangeli, K. R.; Ludgate, K.; Moore, G. M.; Payza, K. Analog of neuropeptide FF attenuates morphine abstinence syndrome. Peptides 12:1011-1014; 1991.
38. Malin, D. H.; Lake, J. R.; Newlin-Maultsby, P.; Roberts, L. K.; Lanier, J. G.; Carter, V. A.; Cunningham, J. S.; Wilson, O. B. A rodent model of nicotine abstinence syndrome. Pharmacol. Biochem. Behav. 43:779-784; 1992.
39. Malin, D. H.; Lake, J. R.; Payne, M. C.; Short, P. E.; Carter, V. A.; Cunningham, J. S.; Wilson, O. B. Nicotine alleviation of nicotine abstinence syndrome is naloxone-reversible. Pharmacol. Biochem. Behav. 53:81-85; 1996.
40. Malin, D. H.; Murray, J. B.; Crucian, G. P.; Schweitzer, F. C.; Cook, R. E.; Skolnick, M. H. Auricular microelectrostimulation: Naloxone reversible attenuation of opiate abstinence syndrome. Biol. Psychiatry 24:886-890; 1988.
41. Ornish, S. A.; Zisook, S.; McAdams, L. A. Effects of transdermal clonidine treatment on withdrawal symptoms associated with smoking cessation. Arch. Int. Med. 148:2027-2031; 1988.
42. Panula, P.; Kivipelto, L.; Nieminen, O.; Majane, E. A.; Yang, H.-Y. T. Neuroanatomy of morphine-modulating peptides. Med. Biol. 65:127-135; 1987.
43. Payza, K.; Akar, C. A.; Yang, H.-Y. T. Neuropeptide FF receptors: Structure-activity relationships and effect of morphine. J. Pharmacol. Exp. Ther. 267:88-94, 1993.
44. Pierzchala, K.; Houdi, A. A.; VanLoon, G. R. Nicotine-induced alterations in brain regional concentrations of native and cryptic Met-and Leu-enkephalin. Peptides 8:1035-1043; 1987.
45. Pomerleau, O. F.; Fertig, J. B.; Seyler, E.; Jaffe, J. Neuroendocrine reactivity to nicotine in smokers. Psychopharmacology (Berlin) 81:61-67; 1983.
46. Pomerleau, O. F. Nicotine and the central nervous system: Biobehavioral effects of cigarette smoking. Am. J. Med. 93(1A):2-8; 1992.
47. Rosecrans, J. A.; Hendry, J. S.; Hong, J. S. Biphasic effects of chronic nicotine treatment on hypothalamic immunoreactive beta-endorphin in the mouse. Pharmacol. Biochem. Behav. 23: 141-143; 1985.
48. Rothman, R. B.; Xu, H.; Yang, H.-Y. T.; Long, J. B. Antiopioid peptides in morphine tolerance and dependence: Focus on NPFF. In: Hammer, R. P., ed. The neurobiology of opiates. Boca Raton: CRC Press; 1993:147-163.
49. Seckl, J. R.; Johnson, M.; Shakespear, C.; Lightman, S. L. Endogenous opioids inhibit oxytocin release during nicotine-stimulated secretion of vasopressin in man. Clin. Endocrinol. 28: 509-514; 1988.
50. Stewart, J. M.; D. Young. Solid phase peptide synthesis. Rockford, IL: Pierce Chemical Co.; 1984.
51. 2-like immunoreactivity. Proc. Natl. Acad. Sci. USA 81:5002-5005; 1984.
52. Tobin, M. J.; Jenouri, G.; Sackner, M. A. Effect of naloxone on change in breathing pattern with smoking. Chest 82:530-537; 1982.
53. Tseng, L.; Loh, H. H.; Wei, E. T. Effects of clonidine on withdrawal signs in the rat. Eur. J. Pharmacol. 30:93-99; 1975.
54. Yang, H.-Y. T.; Fratta, W.; Majane, E. A.; Costa, E. Isolation, sequencing, synthesis, and pharmacological characterization of two brain neuropeptides that modulate the action of morphine. Proc. Natl. Acad. Sci. USA 82:7757-7761; 1985.